Bala Cynwyd, Pennsylvania--(Newsfile Corp. - October 8, 2026) - Law office of Brodsky & Smith announ

Pacira BioSciences stock surges 44% after Viatris announces a $1.65 billion takeover deal to expand

The specialty pharmaceutical company is being acquired.

Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expand

Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and

Investors looking for stocks in the Medical Services sector might want to consider either Viatris (V

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and

UBS analyst Ashwani Verma maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

PITTSBURGH, Oct. 5, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, t

Oppenheimer analyst Les Sulewski initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform ra

Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targe

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises th

Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in

Leerink Partners analyst Daniel Clark initiates coverage on Viatris (NASDAQ:VTRS) with a Outperfo

Argus Research analyst Jasper Hellweg maintains Viatris (NASDAQ:VTRS) with a Buy and raises the p

Viatris sells Tyrvaya to Harrow for up to $100 million, raises 2026 guidance after second-quarter ea

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.69 per share which beat the analyst consensu

Viatris (NASDAQ:VTRS) raises FY2026 Adj EPS guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 analys

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ra

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well ToleratedVR-205 Efficacy and Sa

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Dru

U.S. officials discussed possible SSRI restrictions as RFK Jr. unveiled a broader push to reduce ant

JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the pric

Truist Securities analyst Srikripa Devarakonda maintains Viatris (NASDAQ:VTRS) with a Buy and rai

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Viatris (NASDAQ:VTRS) affirms FY2026 Adj EPS guidance from $2.33-$2.47 to $2.33-$2.47 vs $2.44 analy

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.59 per share which beat the analyst consensu

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

Investors turn to high-yielding dividend stocks in turbulent markets. Benzinga readers can check ana

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga readers can check analyst

Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the

Collaboration expands access to trusted therapies with discounted cash prices for leading brands inc

Viatris (NASDAQ:VTRS) is looking for FY2026 Adj EPS of $2.33-$2.47 vs $2.49 analyst estimate. sees s

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.57 per share which beat the analyst consensu

FDA PDUFA Goal Date Set for October 17, 2026PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises th

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular DiseasesPITTSBU

Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the Company will prese

Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR De

Barclays analyst Glen Santangelo initiates coverage on Viatris (NASDAQ:VTRS) with a Overweight ra